1921
Volume 78, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

The global strategy for the elimination of lymphatic filariasis (LF) is based on annual mass drug administration (MDA) to interrupt transmission. Noncompliance with MDA represents a serious programmatic obstacle for the LF program because systematically noncompliant individuals may serve as a reservoir for the parasite and permit recrudescence of infection. Using a survey questionnaire concerning practices, beliefs, and attitudes towards MDA, we assessed differences between noncompliant individuals and compliant individuals in Leogane, Haiti (n = 367) after four years of treatment. A logistic regression model showed the odds of being noncompliant were significantly increased for women (odds ratio = 2.74, 95% confidence interval = 1.12–6.70), as well as for people who lacked knowledge about both LF and programs to eliminate infection. Public health programs should be designed to target people who are at risk for systematic noncompliance.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2008.78.283
2008-02-01
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/78/2/0780283.html?itemId=/content/journals/10.4269/ajtmh.2008.78.283&mimeType=html&fmt=ahah

References

  1. Molyneux D, 2003. Lymphatic filariasis (elephantiasis) elimination: a public health success and development opportunity. Filaria J 2 : 13.
  2. World Health Organization, 2003. Global Programme to Eliminate Lymphatic Filariasis: Annual Report on Lymphatic Filariasis. Geneva: World Health Organization.
  3. World Health Organization, 2001. Lymphatic filariasis. Wkly Epidemiol Rec 76 : 149–156.
  4. Michael D, Bundy DA, Grenfell BT, 1996. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology 112 : 409–428.
  5. Babu BV, Kar SK, 2004. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9 : 702–709.
  6. Ottesen EA, Duke BOL, Karam M, Behbehani K, 1997. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75 : 491–503.
  7. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD, 2003. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 188 : 1371–1381.
  8. de Rochars MF, Kanjilal S, Direny AN, Radday J, Lafontant JG, Mathieu E, Rheingans RD, Haddix AC, Streit TG, Beach MJ, Addiss DG, Lammie PJ, 2005. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration. Am J Trop Med Hyg 73 : 888–894.
  9. Mathieu E, Direny AN, de Rochars MB, Streit TG, Addiss DG, Lammie PJ, 2006. Participation in three consecutive mass drug administrations in Leogane, Haiti. Am J Trop Med Hyg 11 : 862–868.
  10. Pichon G, 2002. Limitation and facilitation in the vectors and other aspects of the dynamics of filarial transmission: the need for vector control against Anopheles-transmitted filariasis. Ann Trop Med Parasitol 96 : S143–S153.
  11. Esterre P, Plichart C, Sechan Y, Nguen L, 2001. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop Med Int Health 6 : 190–195.
  12. Mathieu E, Lammie PJ, Radday J, Beach MJ, Streit T, Wendt J, Addiss DG, 2004. Factors associated with participation in a campaign of mass treatment against lymphatic filariasis in Leogane, Haiti. Ann Trop Med Parasitol 98 : 703–714.
  13. Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, Vijay Kurnar KN, Chandrakala AV, 2000. A program to eliminate lymphatic filariasis in Tamil Nadu state, India compliance with annual single-dose DEC mass treatment and some related operational aspects. Trop Med Int Health 5 : 842–847.
  14. de Rochars M, Direny AN, Roberts JM, Addiss DG, Radday J, Beach MJ, Streit TG, Dardith D, Lafontant JG, Lammie PJ, 2004. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs. Am J Trop Med Hyg 71 : 466–470.
  15. Brady MA, Hooper PJ, Ottesen EA, 2006. Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol 22 : 285–291.
  16. World Health Organization, 2006. Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions; A Manual for Health Professionals and Programme Managers. Geneva: World Health Organization.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.78.283
Loading
/content/journals/10.4269/ajtmh.2008.78.283
Loading

Data & Media loading...

  • Received : 06 Jul 2007
  • Accepted : 25 Oct 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error